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PROSTASOMAL STRUCTURE
Prostasomes are found in high concentrations 
in seminal plasma. Under electron microscopy 
there appear to be two distinct morphological 
types: smaller, ‘dark’ prostasomes with tightly 
packed electron-dense contents, and larger 
‘light’ less dense structures (Fig. 1). Their 
diameter is 40–500 nm [1]. They have a lipid 
bilayer membrane which may be arranged 
in a multilamellar fashion, and has a 
characteristically high concentration of 
cholesterol. Consequently, prostasomes have 
a membrane which is less permeable to small 
water-soluble molecules. Analogous 
structures are also shed by prostate cell lines 
into culture media [2].
 
PREPARATION OF PROSTASOMES
 
Prostasomes can be prepared from both 
 
in-vitro
 
 and 
 
in-vivo
 
 sources, using semen, 
prostatic tissue (benign, primary and 
secondary malignancy) or prostate cancer cell 
lines. Although the finer details of extraction 
will depend upon the source, the protocols 
used to isolate prostasomes contain the 
following elements:
• Removal of cells from semen by low-speed 
centrifugation.
• Ultracentrifugation of seminal plasma, e.g. 
100 000 
 
g
 
 for 2 h.
• Re-suspension of the prostasome pellet, 
typically in isotonic Tris-HCl buffer.
• Gel chromatography, e.g. using a ‘superdex’ 
column, to purify the re-suspended 
prostasome containing fractions.
 
BIOCHEMISTRY
 
LIPIDS
One of the main lipid components of 
prostasomes is sphingomyelin [1], a 
phospholipid, which contains 1-
phosphocholine combined with a ceramide 
(an N-acyl long-chain base) such as 
sphingosine. Sphingomyelin is one of the 
main constituents of the myelin sheath of 
neurones. More than half of the phospholipid 
component of the prostasomal membrane is 
either palmitic (COOH(CH
 
2
 
)
 
14
 
CH
 
3
 
) or stearic 
acid (COOH(CH
 
2
 
)
 
16
 
CH
 
3
 
). The ratio of 
cholesterol to phospholipid is about 2 : 1, 
compared to 1 : 1 in a typical mammalian cell 
membrane [1].
PROTEINS
A recent proteomic analysis using an HPLC-
mass spectrometry approach trawled 139 
associated proteins in prostasomes isolated 
from pooled semen [3]. The authors 
hypothesise that prostatic diseases may 
present unique phenotypes at the level of 
their respective prostasomal proteomes. Some 
previously identified proteins (e.g. CD142, see 
below) do not appear in this analysis; 9% 
appeared to be novel. The functions of the 
‘known’ molecules are diverse and include 
structural membrane proteins, enzymes, 
chaperone proteins and signal transduction 
molecules. Some have particular relevance 
in the genitourinary tract and inform 
speculation on the biological effects of the 
prostasome; Table 1 [4–14] lists some of the 
more interesting candidates, but the exact 
function of many prostasomal proteins 
remains unclear.
Tissue factor (TF), 
 
alias
 
 thromboplastin or CD 
142, is a transmembrane glycoprotein with a 
molecular weight of 
 
ª
 
29 kDa. It is a receptor 
and essential cofactor for clotting factors VII 
and VIIa, and acts as the main physiological 
initiator of the coagulation cascade. TF is 
present in human semen, predominantly in 
the prostasomal fraction, and has been 
located on the prostasomal surface using 
immuno-electron microscopy (Table 1 [11]).
Neuroendocrine components, e.g. 
neuropeptide Y, chromogranin A and B, 
and vasoactive intestinal peptide, have 
also been detected in prostasomes by 
radioimmunoassay. Skibinsky 
 
et al.
 
 [10] 
identified the secretory granule protein 
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INTRODUCTION
 
Prostasomes are membrane-bound secretory 
vesicles, in the nanometre diameter range, 
secreted by the prostatic ductal epithelium [1] 
into the lumen, where they form part of the 
ejaculate. Although known to have specific 
biological properties, their physiological role 
and overall significance remain far more 
debatable. There has been comparatively little 
written about these structures since their 
detection two decades ago, and this may help 
explain the relative lack of awareness of 
prostasomes within the urological 
community.
 
ORIGIN AND PHYSICAL PROPERTIES
 
PRODUCTION AND SECRETION 
OF PROSTASOMES
Prostasomes are produced in the apical part 
of the prostatic ductal epithelial cell where 
the Golgi apparatus is abundant. Many 
prostasomes appear together within larger 
storage vesicles before secretion into the 
prostatic ductal lumen. There are thought to 
be two main modes of prostasome secretion. 
In exocytosis, larger storage vesicles fuse with 
the cell membrane to discharge their 
contents, followed by recycling of the 
vesicular membrane. Secretion in membrane-
bound form, or diacytosis, involves the whole 
storage vesicle together with its contained 
prostasomes being translocated through the 
membrane (as happens with hepatic 
phospholipids). They are thought to occur 
with about equal frequency [1]. This is 
supported by the morphological finding of 
both free prostasomes and membrane-bound 
groups of prostasomes within the ductal 
lumen.
 S T E W A R T  
 
E T  A L .
 
9 8 6
 
©
 
 2 0 0 4  B J U  I N T E R N A T I O N A L
 
granulophysin, which is structurally similar to 
the neuroprotein synaptophysin (Table 1).
 
PROSTASOMAL FUNCTION
 
Function depends on the source of 
prostasomes; for instance, if sperm motility is 
considered, prostasomes isolated from PC3 
cell lines have similar properties to those 
isolated from seminal plasma [15], whereas 
amino-peptidase activity differs [2]. The 
identification of prostasome-associated 
proteins sheds light on the possible function 
of prostasomes (Table 1 [4–14]). It is 
postulated that they have a role in sperm 
motility, semen calcium homeostasis, semen 
liquefaction, complement inhibition, 
immunosuppression, prevention of 
haematogenous infection, clotting activation, 
and even a role in HIV transmission. They are 
also reputed to have antioxidant properties.
 
SPERM-PROSTASOME INTERACTIONS
 
The evidence suggests that by sperm 
prostasome-interaction, advantageous 
effects of prostasomal membrane proteins are 
conferred to the sperm cell, resulting in an 
improved microenvironment and an increased 
chance of the sperm cell achieving successful 
fertilization. Sperm fusion with prostasomes 
has been an area of some interest. Ronquist 
 
et 
al.
 
 [16] reported that both the spermatozoa 
and prostasomes have a net negative surface 
charge, with the prostasome being less 
negative. Fusion occurs despite the expected 
repulsion, raising further questions about 
sperm-prostasomal interaction. It has been 
shown that fusion between sperm and 
prostasomes is Ca
 
2
 
+
 
-dependent and involves 
increasing sperm intracytoplasmic Ca
 
2
 
+
 
 
concentrations (Table 1 [12]).
Fabiani 
 
et al.
 
 [17] showed an increase in sperm 
motility in semen samples treated with 
prostasomal preparations, with a response 
rate of up to 70%. Motility may even occur in 
sperm that are initially deemed to be 
immotile. The increased sperm motility 
attributable to prostasomes is pH-dependent. 
This may be physiologically significant, as 
sperm encounter an acidic environment on 
ascending the female genital tract. Sperm 
motility was shown by Arienti 
 
et al.
 
 [18] to be 
decreased in an acidic environment, but this 
was improved by adding prostasomes. Thus, it 
is possible that prostasomes offer some 
buffering protection for the sperm against the 
relatively harsh vaginal/uterine environment. 
However, these discoveries do not appear to 
have led to widespread clinical application 
within infertility management, perhaps 
raising doubts about the overall significance 
of the results.
Prostasomes are thought to promote sperm 
motility by modulating calcium ion 
concentrations. Prostasomes are rich in 
calcium ions and the prostasome-associated 
Ca/Mg ATPase system may control their 
transport across the prostasome membrane. 
Annexins and calmodulin are other proteins 
involved with Ca
 
2
 
+
 
 regulation that are present 
in prostasomes.
Although the mechanisms involved in the 
acrosome reaction are not completely 
understood, Arienti 
 
et al.
 
 [19] suggested that 
the sperm membrane appears to stabilise on 
fusing with prostasomes because of 
enrichment with cholesterol, sphingomyelin, 
and saturated glycerophospholipid. It is 
argued that this may ‘prevent the untimely 
occurrence of the acrosome reaction’ [19]. The 
significance of other molecules, including 
arachidonic acid 15-lipoxygenase, has also 
been noted; it has been implicated in the 
acrosome reaction of bull semen and was 
found by Oliw 
 
et al.
 
 [20] to be present in 
purified human prostasomes.
 
SEMEN COAGULATION 
AND LIQUEFACTION
 
Immediately after ejaculation normal 
human semen coagulates. The coagulum 
is largely composed of the of sialo-
glycoprotein-metal complexes 
(semenogelins), glycerylphosphorylcholine 
and fibronectin, the whole being known as 
high molecular weight seminal vesical 
 
TABLE 1 
 
Prostasomal proteins and their putative functions
 
Protein Putative function Reference
CD 13, aminopeptidase Zinc-dependent proteolytic enzyme. Liquefaction of semen. [4]
CD 26, dipeptidyl peptidase IV Peptide metabolism, T-lymphocyte activation and the regulation of DNA synthesis, cell
proliferation and the production of cytokines. HIV binding.
[5]
CD 10, enkephalinase
(neutral endopeptidase)
Membrane-anchored ectoenzyme (peptidase). Regulation of growth stimulatory capacity
Lost in hormone-insensitive invasive prostate cancer cell lines
Angiotensin 2 and bradykinin metabolism
[6]
[7]CD 143, angiotensin converting
enzyme
CD 46, 55, 59 Complement inhibitors. Sperm motility. Protection of sperm against complement attack
in the female genital tract
[8,9]
CD 69, granulophysin Facilitate molecular interactions. Increasing the formation and stability of functional
signalling complexes
[10]
CD 142, TF Rapid activation of clotting, preventing bleeding and transfer of infection [11]
ATPase Vectorial calcium transport into prostasomes. Prostasomes are rich in Ca
 
2
 
+
 
, and
participate in the maintenance of Ca
 
2
 
+
 
 homeostasis which is necessary for sperm motility
[12]
Ca/Mg dependent heat-shock
proteins, including Hsp70 and 90
Chaperon proteins. Promotion of protein folding, assembly, translocation and secretion
of newly formed polypeptides. Hsp 90 targets signal transduction proteins, e.g. steroid
hormone receptors and signalling kinases
[13]
PSA Tumour marker for prostate cancer. Semen liquefaction. [14]
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proteins (HMW-SVP) [21]. Within 
 
ª
 
20 min, 
spontaneous liquefaction occurs by the 
action of PSA (a serine protease present in 
seminal plasma, both free and prostasome-
associated [3]) and possibly the involvement 
of prostasome aminopeptidase, a zinc-
dependent proteolytic enzyme (Table 1 [4]).
 
THE HAEMOSTATIC SYSTEM IN SEMEN
 
There is evidence that most of the 
components of the blood coagulation and 
fibrinolytic system are present in semen. There 
are points of contact between these and the 
HMW-SVP system, notably PSA, which binds 
to protein-C inhibitor. Moreover, digestion of 
semenogelin with PSA produces fragments 
which cross-link into complexes with clotting 
Factor XIIIa [22]. This circumstance is a 
reminder not to assign exclusive categories to 
groups of molecules; semen contain many 
interrelating proteases. Because of its 
prostasomal (and perhaps some soluble) TF 
content, semen has potent blood-clotting 
activity. The ability to coagulate blood rapidly 
from abrasions during intercourse is 
postulated to prevent sperm and seminal 
components, including infectious agents such 
as HIV, from entering the blood stream, 
generating antibodies, or promoting 
infectious disease.
 
EFFECTS ON THE LYMPHORETICULAR 
SYSTEM AND IMMUNITY
 
Human semen has potent 
immunosuppressive activity [23], thought to 
help protect sperm from immunological 
attack within the female reproductive tract. 
Local immunosuppression may also help to 
protect the female genital tract from 
becoming sensitized to the allo-antigenic 
proteins present in seminal plasma and on 
sperm.
Prostasomes inhibit lymphocyte proliferation 
and protect sperm cells from macrophage 
phagocytosis [24]. CD46,55 and 59 on 
prostasomes have been shown to regulate 
complement pathways and opsonization 
(Table 1 [8,9]). CD46 causes proteolytic 
inactivation of factors C3b and C4b of the 
complement cascade. CD55, the decay 
accelerating factor, and CD59, an inhibitor of 
the membrane attack complex, both protect 
from complement-mediated lysis and 
phagocytosis.
 
HIV INFECTION
 
Prostasomes may facilitate HIV binding 
and survival in human semen. CD26 
(dipeptidylpeptidase), a prostasomal 
membrane protein, binds HIV (Table 1 [5]). 
Second, the complement inhibitors CD46, 55 
and 59 that protect sperm may also protect 
the HIV virus. Indeed CD55 and CD59 might 
become transferred from the prostasome to 
the HIV membrane (Table 1 [8]).
 
ANTIOXIDANT PROPERTIES
 
Reactive oxygen species or free radicals are 
pivotal in inflammation and carcinogenesis. 
They are harmful to sperm and a major 
cause of idiopathic male infertility. 
Polymorphonuclear leukocytes in semen are 
thought to be a major local source of reactive 
oxygen species. The addition of prostasomes 
to polymorphonuclear leukocytes caused a 
reduction of these free radicals [25]. The 
authors attributed this decrease not to free-
radical scavenging, but the incorporation of 
16-doxyl-stearate into the cell membranes, 
increasing rigidity.
 
THE ROLE OF PROSTASOMES 
IN UROLOGICAL DISEASE, AND 
CURRENT RESEARCH
 
Prostate cancer cells generate prostasome-
like granules [2]; antibodies to prostasomes 
have been detected in the serum of patients 
with prostate cancer. A pilot study by Nilsson 
 
et al.
 
 [26], using ELISA technology, showed 
markedly higher serum levels of antibodies to 
prostasomes in patients with prostate cancer 
than in control subjects. This work used a 
prostasome-like preparation made from 
prostate tissue. Our ongoing and as yet 
unpublished experimental results, using 
seminal prostasomes from vasectomized men 
as antigen, give a much lower rate of 
positivity in sera from patients with prostate 
cancer. Further work is required to establish 
the role of antibodies to prostasomes as 
prognostic indicators and determinants in 
tumour progression. The antigenic target(s) 
need identifying. Nilsson’s group chose a 
monoclonal antibody for their studies, and 
thus detected antibodies to one epitope only 
on these complex structures. It is not 
apparent how many specificities emerged 
from their fusions. The metastatic status of 
the patients in that study was not recorded. 
Local invasion or metastasis should facilitate 
prostasomes escaping into the vascular and 
lymphatic systems. Leaked prostasomes may 
also impinge on the course of whatever 
pathological process caused their presence 
there, for good or ill. The ease with which 
prostasomal membrane elements apparently 
fuse with cells and pathogens gives much 
scope for them to influence events.
Relatively little has been published on the 
potential role of prostasomes in urological 
disease. Recent work by Carlsson 
 
et al.
 
 [27] 
suggests that prostasomes have a growth 
inhibitory effect on prostatic cancer cell lines 
in culture, with the effect being most marked 
with DU145 cells. The possibility of 
 
in-vivo
 
 
growth-inhibition should therefore be 
considered.
 
FIG. 1. 
 
Transmission electron microscopy of (a) dark 
prostasomes, diameter 
 
ª
 
150 nm, and (b) light 
prostasomes, the diameter of large light 
prostasomes being 
 
ª
 
300 nm.
a
b
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TF has been implicated in breast cancer as a 
marker for the switch to an angiogenic 
phenotype. The role, if any, of prostasome-
bound TF in prostate cancer angiogenesis has 
yet to be determined. Malignancy has long 
been associated with hypercoagulability, 
presumably involving TF. Urinary exosomes, 
derived from kidney tubular epithelium, also 
carry TF [28], and their potential as diagnostic 
or prognostic markers of malignancy is well 
described [29]. Abdulkadir 
 
et al.
 
 [30] 
implicated urinary TF expression as being 
correlated with PSA levels in prostate 
carcinoma, and the procoagulant activity of 
prostatic tissue in an experimental model of 
prostate cancer in rats was highest in 
metastatic disease [31].
 
CONCLUSIONS
 
Prostasomes are relatively neglected entities, 
certainly in urology. The search term 
‘prostasomes’ reveals only 81 papers in 
Pubmed, averaging four per year since their 
discovery. There is an overview of the field 
from other than a urological perspective [32]. 
Prostasomes are best known in domains of 
human and veterinary fertility, but given their 
readiness to fuse with cells, their content of 
potentially influential molecules, and 
antioxidant properties, it can be argued that 
prostasomes are more than just vehicles for 
the disposal of unwanted cellular material. 
This may or may not be the case for the 
exosomes produced by prostate cell lines 
 
in 
vitro
 
 and caution should be exercised in 
assuming homology. There are also 
seminosomes, liberated in the testis and 
presumably contaminating prostasome 
preparations (except in vasectomized 
individuals). Indeed, experimental 
comparisons between prostatic exosomes 
and those released by other epithelia 
would help to differentiate the specific 
prostasomal properties from more general 
attributes.
There is circumstantial evidence that 
prostasomes might have some influence on 
proliferative events in the prostate. Antibodies 
that react with prostasomes, whatever the 
original immunogen, are intriguing both for 
their very existence and the opportunities for 
the pathophysiological effect they suggest. It 
is timely for academic urologists to address 
the pathophysiology of prostasomes, in 
particular more prostate-specific issues, e.g. 
prostatic carcinoma, prostatitis and BPH.
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